ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Novartis/Spark’s sight gene therapy approved in EU
pharmaphorum
November 27, 2018Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there was still no word on price from marketing partner Novartis.
Pharma Sources Insight January 2025
